Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

Invivyd to announce Phase 3 COVID-19 trial results Monday

Invivyd to announce Phase 3 COVID-19 trial results Monday

Invivyd, Inc. (NASDAQ:IVVD) is set to announce the results of its Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate designed to treat COVID-19, on Monday, November 23, 2026. The company will host an investor call at 8:30 a.m. ET following the announcement, which is expected to be made at 7:00 a.m. ET. VYD2311, developed using Invivyd’s technology platform, shares a similar antibody backbone with pemivibart and adintrevimab, both of which have received emergency use authorization for specific COVID-19 treatments.

The trial results will be made available on the company’s investor website via a webcast replay approximately two hours after the call concludes.

Brief written by urgent.news; may contain errors — check the original.

Source: investing.com

Read the original at investing.com →

Report a problem with this story

More in Health & Medicine

DiaRhythm - Diabetes management routines

This is a submission for the Presage SmartSpectra SDK Challenge What I Built DiaRhythm is a local first desktop companion for diabetes-management routines, with an optional contactless…

  • DiaRhythm is a local-first Electron app for diabetes management
  • Users can log glucose readings, medications, meals, activities
  • Optional SmartSpectra feature measures breathing rate via camera

More from Sunday 22 November →